FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Reviewers Concerned About Data Supporting Replimune Melanoma BLA

[ Price : $8.95]

FDA reviewers raise concerns about the clinical evidence supporting Replimune Group's BLA resubmission for accelerated approval of...

Linemaster Switch QS Violations

[ Price : $8.95]

FDA warns Woodstock, CT-based Linemaster Switch Corp. about Quality System violations in its production of medical device foot ped...

FDA: VasoCorp Selling Unapproved, Misbranded Drugs

[ Price : $8.95]

FDA warns Hiram, GA-based VasoCorp Inc. that it is illegally marketing misbranded unapproved new drugs.

PhRMA Urges FDA to Clarify Drug Dose Modeling Guidance

[ Price : $8.95]

The Pharmaceutical Research and Manufacturers of America urges FDA to revise and clarify its draft guidance on using quantitative ...

Alkem Labs Plant in India Cited Over OOS Investigations, Quality Systems

[ Price : $8.95]

FDA issues a 26-page Form 483 to Alkem Laboratories following an 4/20-5/1 inspection of the company's finished drug manufacturing ...

17 Revised Draft Guidances for Certain Generic Peptide Products

[ Price : $8.95]

FDA posts 17 revised draft product-specific guidances for peptide products, which it touts as a significant advancement in the age...

FDA Accepts for Review Saol Therapeutics SL1009 NDA Resubmission

[ Price : $8.95]

FDA accepts for review a Saol Therapeutics NDA resubmission for SL1009 (sodium dichloroacetate, or DCA), an investigational treatm...

5 Observations in 17-Page Strides Pharma FDA-483

[ Price : $8.95]

FDA releases the 17-page form FDA-483 following a May inspection at Indias Strides Pharma Science drug manufacturing facility in B...

FDA Sends Congress FY 2024 Pediatric Device Approval Report

[ Price : $8.95]

In its report on FY 2024 approvals of medical devices for pediatric uses, FDA says that 19 of the 56 device approvals that year we...

Novel Laboratories FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 with three observations from an inspection at the Novel Laboratories (Lupin) drug manufacturing faci...